Annexon, Inc.
ANNXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. At a $701.4M market cap, Annexon, Inc. ranks as a small-cap company within healthcare. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Market Cap
$701.4M
Beta
1.33
P/E (TTM)
—
P/E (Fwd)
-3.45
EPS (TTM)
$-1.13
EPS (Fwd)
$-1.07
ROE
-105.3%
ROA
-51.5%
Cash
$209.2M
Total Debt
$24.7M
Free CF
-$116.0M
52W Change
4.5%
Annual Financials
Cash vs Debt
Where ANNX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ANNX finished 22.29% below its 150-day moving average ($5.16) and 24.20% below its 200-day moving average ($5.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ANNX overbought or oversold?
At the October 20, 2026 close, ANNX's RSI(14) was 46.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $209.2M in cash comfortably exceeding the $24.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$116.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -105.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Annexon, Inc. and its sector.